Influence of GABAA and GABAB receptor activation on auditory sensory gating and its association with anxiety in healthy volunteers

IF 4.5 3区医学 Q1 CLINICAL NEUROLOGY

Journal of Psychopharmacology Pub Date : 2024-04-22 DOI:10.1177/02698811241246854

Sara de la Salle, Justin Piche, Brittany Duncan, Joëlle Choueiry, Molly Hyde, Robert Aidelbaum, Ashley Baddeley, Danielle Impey, Noreen Rahmani, Vadim Ilivitsky, Verner Knott

{"title":"Influence of GABAA and GABAB receptor activation on auditory sensory gating and its association with anxiety in healthy volunteers","authors":"Sara de la Salle, Justin Piche, Brittany Duncan, Joëlle Choueiry, Molly Hyde, Robert Aidelbaum, Ashley Baddeley, Danielle Impey, Noreen Rahmani, Vadim Ilivitsky, Verner Knott","doi":"10.1177/02698811241246854","DOIUrl":null,"url":null,"abstract":"Background:Dysfunctional sensory gating in anxiety disorders, indexed by the failure to inhibit the P50 event-related potential (ERP) to repeated stimuli, has been linked to deficits in the major inhibitory neurotransmitter γ-aminobutyric acid (GABA).Aims/Methods:This study, conducted in 30 healthy volunteers, examined the acute effects of GABAA (lorazepam: 1 mg) and GABAB receptor (baclofen: 10 mg) agonists on P50 measures of auditory sensory gating within a paired-stimulus (S1-S2) paradigm and assessed changes in gating in relation to self-ratings of anxiety.Results:Compared to placebo, lorazepam reduced ERP indices of sensory gating by attenuating response to S1. Although not directly impacting P50 inhibition, baclofen-induced changes in gating (relative to placebo) were negatively correlated with trait but not state anxiety.Conclusions:These preliminary findings support the involvement of GABA in sensory gating and tentatively suggest a role for GABAB receptor signaling in anxiety-associated gating dysregulation.","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":"18 1","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02698811241246854","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background:Dysfunctional sensory gating in anxiety disorders, indexed by the failure to inhibit the P50 event-related potential (ERP) to repeated stimuli, has been linked to deficits in the major inhibitory neurotransmitter γ-aminobutyric acid (GABA).Aims/Methods:This study, conducted in 30 healthy volunteers, examined the acute effects of GABAA (lorazepam: 1 mg) and GABAB receptor (baclofen: 10 mg) agonists on P50 measures of auditory sensory gating within a paired-stimulus (S1-S2) paradigm and assessed changes in gating in relation to self-ratings of anxiety.Results:Compared to placebo, lorazepam reduced ERP indices of sensory gating by attenuating response to S1. Although not directly impacting P50 inhibition, baclofen-induced changes in gating (relative to placebo) were negatively correlated with trait but not state anxiety.Conclusions:These preliminary findings support the involvement of GABA in sensory gating and tentatively suggest a role for GABAB receptor signaling in anxiety-associated gating dysregulation.

查看原文本刊更多论文

GABAA 和 GABAB 受体激活对健康志愿者听觉门控的影响及其与焦虑的关系

背景：焦虑症患者的感觉门控功能失调（以无法抑制重复刺激的 P50 事件相关电位（ERP）为指标）与主要抑制性神经递质γ-氨基丁酸（GABA）的缺陷有关。目的/方法：本研究在30名健康志愿者中进行，考察了GABAA（劳拉西泮：1毫克）和GABAB受体（巴氯芬：10毫克）激动剂在成对刺激（S1-S2）范式中对听觉门控P50测量的急性影响，并评估了与焦虑自我评分相关的门控变化。结果：与安慰剂相比，劳拉西泮通过减弱对S1的反应降低了感觉门控的ERP指数。结论：这些初步研究结果支持GABA参与感觉门控，并初步提出了GABAB受体信号在焦虑相关门控失调中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Psychopharmacology 医学-精神病学

CiteScore

8.60

自引率

4.90%

发文量

126

审稿时长

3-8 weeks

期刊介绍： The Journal of Psychopharmacology is a fully peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology. The journal provides an essential forum for researchers and practicing clinicians on the effects of drugs on animal and human behavior, and the mechanisms underlying these effects. The Journal of Psychopharmacology is truly international in scope and readership.